Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28106523 | 0.85 | ACHE (0.43) | ACHECCNT1CCNA2CDK2CDK9 | |
| SCHEMBL5491642 | 0.80 | PIK3CA (0.46) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL30600608 | 0.78 | SUV39H2 (0.38) | ACHETSHRCYP1A2MAPK1 | |
| SCHEMBL13033008 | 0.78 | KMT2A (0.56) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL26684341 | 0.77 | ACHE (0.55) | ACHEKDM4ECYP1A2 | |
| SCHEMBL5457199 | 0.76 | PIK3CA (0.55) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL5525967 | 0.76 | PIK3CA (0.58) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL18765579 | 0.76 | PIK3CA (0.43) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL17827961 | 0.75 | PIK3CA (0.51) | PIK3CAPIK3R1PIK3CDPIK3CBACHE | |
| SCHEMBL1110254 | 0.75 | PIK3CA (0.54) | PIK3CAPIK3R1PIK3CDPIK3CBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-9533959-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-9296727-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | PIK3CA 479/4885PIK3R1 3825/4885PIK3CD 1279/4885 |
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | PIK3CA 2810/4885PIK3R1 940/4885PIK3CD 1632/4885 |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | PIK3CA 479/4885PIK3R1 3825/4885PIK3CD 1279/4885 |
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | TYMS, UMPS, DPYD | PIK3CA 479/4885PIK3R1 3825/4885PIK3CD 1279/4885 |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | PIK3CA 479/4885PIK3R1 3825/4885PIK3CD 1279/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | PIK3CA 2810/4885PIK3R1 940/4885PIK3CD 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.